Pillar Biosciences Announces Expansion of NGS Commercial Partnership with Illumina

On October 16, 2024 Pillar Biosciences, Inc., the leader in Decision Medicine, reported an expansion of their existing partnership with Illumina, through which a broader portfolio of Pillar’s oncoReveal NGS panels will now be offered directly by Illumina (Press release, Pillar Biosciences, OCT 16, 2024, View Source [SID1234647235]). Several of Pillar’s oncology panels will be available as part of the validated libraries on the MiSeq i100 Series sequencing platform, which launched last week.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

The additional research-use-only (RUO) oncology NGS panels manufactured by Pillar Biosciences and available directly through Illumina will include:

Liquid Biopsy Tumor Profiling:

oncoReveal Core LBx
oncoReveal Essential LBx
oncoReveal Fusion LBx
Solid Tumor Profiling:

oncoReveal Multicancer RNA Fusion (18-Driver gene RNA panel)
oncoReveal Solid Tumor v2 (48-gene DNA panel)
These panels are enabled on the MiSeq and NextSeq 550 Systems. Pillar Biosciences panels that are enabled on the newly launched Illumina MiSeq i100 Series include:

oncoReveal Essential MPN
oncoReveal Myeloid
oncoReveal Multi-Cancer with CNV and Fusion Panel
oncoReveal BRCA1 & BRCA2 plus CNV Panel
"As part of Illumina’s commitment to address our customers’ total workflow, we are pleased to bring more oncology assays from Pillar Biosciences into our product lineup, including the new MiSeq i100 Series," said Angela Ryan, Vice President, Product Management at Illumina.

"We are excited about the commercial progress generated through our collaboration with Illumina over the past 18 months. By expanding their oncology offering with rapid, high-quality targeted genomic content we can ensure more customers have a full suite of NGS solutions to fulfill their genomic profiling needs," said Dan Harma, Chief Commercial Officer at Pillar Biosciences. "Pillar and Illumina’s NGS solutions are complementary and have very specific technical benefits. These can be utilized together efficiently. We look forward to working together to better enable our customers and further driving localized NGS services."